ATA107397A - Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons - Google Patents

Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Info

Publication number
ATA107397A
ATA107397A AT107397A AT107397A ATA107397A AT A107397 A ATA107397 A AT A107397A AT 107397 A AT107397 A AT 107397A AT 107397 A AT107397 A AT 107397A AT A107397 A ATA107397 A AT A107397A
Authority
AT
Austria
Prior art keywords
cell clone
serum
protein
obtaining
free medium
Prior art date
Application number
AT107397A
Other languages
English (en)
Other versions
AT407255B (de
Inventor
Manfred Reiter
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3506017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA107397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT0107397A priority Critical patent/AT407255B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to US09/100,253 priority patent/US6100061A/en
Priority to US09/324,612 priority patent/US6475725B1/en
Publication of ATA107397A publication Critical patent/ATA107397A/de
Application granted granted Critical
Publication of AT407255B publication Critical patent/AT407255B/de
Priority to US10/170,661 priority patent/US6936441B2/en
Priority to US11/123,362 priority patent/US7094574B2/en
Priority to US11/482,504 priority patent/US20070161079A1/en
Priority to US12/488,441 priority patent/US20090258391A1/en
Priority to US12/488,465 priority patent/US8080414B2/en
Priority to US12/778,776 priority patent/US8084251B2/en
Priority to US12/848,897 priority patent/US8084252B2/en
Priority to US12/986,111 priority patent/US8329465B2/en
Priority to US14/567,942 priority patent/USRE46745E1/en
Priority to US15/203,558 priority patent/USRE46860E1/en
Priority to US15/203,550 priority patent/USRE46897E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT0107397A 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons AT407255B (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US09/100,253 US6100061A (en) 1997-06-20 1998-06-19 Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US09/324,612 US6475725B1 (en) 1997-06-20 1999-06-02 Recombinant cell clones having increased stability and methods of making and using the same
US10/170,661 US6936441B2 (en) 1997-06-20 2002-06-12 Recombinant cell clones having increased stability and methods of making and using the same
US11/123,362 US7094574B2 (en) 1997-06-20 2005-05-06 Recombinant cell clones having increased stability and methods of making and using the same
US11/482,504 US20070161079A1 (en) 1997-06-20 2006-07-07 Recombinant cell clones having increased stability and methods of making and using the same
US12/488,441 US20090258391A1 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using same
US12/488,465 US8080414B2 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using the same
US12/778,776 US8084251B2 (en) 1997-06-20 2010-05-12 Recombinant cell clones having increased stability and methods of making and using the same
US12/848,897 US8084252B2 (en) 1997-06-20 2010-08-02 Recombinant cell clones having increased stability and methods of making and using the same
US12/986,111 US8329465B2 (en) 1997-06-20 2011-01-06 Recombinant cell clones having increased stability and methods of making and using the same
US14/567,942 USRE46745E1 (en) 1997-06-20 2014-12-11 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,558 USRE46860E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,550 USRE46897E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Publications (2)

Publication Number Publication Date
ATA107397A true ATA107397A (de) 2000-06-15
AT407255B AT407255B (de) 2001-02-26

Family

ID=3506017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Country Status (2)

Country Link
US (1) US6100061A (de)
AT (1) AT407255B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
AU4330597A (en) * 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
BR0114373A (pt) * 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EP1434857B1 (de) * 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Verfahren zur herstelllung rekombinanter proteine in eukaryontischen zellen
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
JP3916516B2 (ja) * 2002-06-10 2007-05-16 独立行政法人科学技術振興機構 硬組織−軟組織界面再生用足場材料
EP2287288B1 (de) 2002-07-09 2012-11-07 Baxter International Inc. Tierproteinfreies Zellkulturmedium
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
CA2519873C (en) * 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
RU2373282C2 (ru) * 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
EP1697505A1 (de) * 2003-12-23 2006-09-06 Schering Corporation Methoden zur herstellung von a549 zelllinien, die in serumfreiem medium in suspensionskultur stabil sind
KR20070008645A (ko) * 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
EP1789096A4 (de) 2004-09-07 2009-07-08 Archemix Corp Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1851305B1 (de) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
ES2474573T3 (es) * 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
EP2423307A1 (de) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IV-Polypeptide und deren Verwendung bei der Behandlung
CA2683317C (en) * 2007-04-26 2014-12-16 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
SG187397A1 (en) 2007-12-27 2013-02-28 Baxter Int Cell culture processes
CA2716801A1 (en) * 2008-03-12 2009-09-17 Wyeth Llc Methods for identifying cells suitable for large-scale production of recombinant proteins
PT2356247E (pt) 2008-11-12 2015-10-26 Baxalta Inc Método de produção de fator vii isento de soro e de insulina
CN104962539B (zh) 2009-07-31 2019-09-17 百深公司 用于adamts蛋白表达的细胞培养基
PL4218797T3 (pl) 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9534037B2 (en) 2011-08-02 2017-01-03 Baxalta GmbH Systems and methods to increase protein yield from recombinant manufacturing processes
HUE056073T2 (hu) 2013-03-15 2022-01-28 Genzyme Corp Magas denzitású sejtbanki tárolási eljárások
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6190205B2 (ja) * 2013-08-08 2017-08-30 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株、その製造方法及び培地
JP6195191B2 (ja) * 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
US20160100570A1 (en) 2014-09-18 2016-04-14 Genzyme Corporation Ultra-high density cell banking methods
US20230203469A1 (en) 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
CA2205015C (en) * 1994-11-10 2003-04-08 Otfried Kistner Method for producing biologicals in protein-free culture
WO1996026266A1 (en) * 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
AUPN442295A0 (en) * 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells

Also Published As

Publication number Publication date
AT407255B (de) 2001-02-26
US6100061A (en) 2000-08-08

Similar Documents

Publication Publication Date Title
ATA107397A (de) Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
HUP9900995A3 (en) Artificial stone for stabilising traffic areas in the open
NO20001242L (no) April - et nytt protein med veksteffekter
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
IL130396A0 (en) OB fusion protein compositions and methods
DK0712862T3 (da) Selektiv acylering af epsilon-aminogrupper i insulin
DE69710487D1 (de) Stabiler standbeutel und verfahren zur herstellung
DK0802941T3 (da) Biologisk nedbrydelige polymerer, fremgangsmåde til fremstilling deraf, samt deres anvendelse til fremstilling af biologisk
DE69631796D1 (de) Verfahren und zusammensetzung zur reduktion der säure in kaffee
FI952679L (fi) Uusia seoksia, menetelmä niiden valmistamiseksi sekä niiden käyttö päällystyksiin
DE69904062D1 (de) Fischer-tropsch-dieselbrennstoff mit verbesserter stabilität und verfahren zu dessen herstellung
DK0809666T4 (da) Biologisk nedbrydelige polymerer, fremgangsmåder til deres fremstilling samt deres anvendelse til fremstilling af bionedbrydelige formlegemer
DE69700813D1 (de) Verwendung von stabilen aminofunktionellen latexen in wässrigen tinten
DE69901178D1 (de) Nichtgesinterte elektrode und verfahren zur herstellung
DE69815789D1 (de) Kniegelenkendprothese mit verbesserter hinterer Stabilität und Massnahmen zur Verhinderung einer Dislokation
DE59915087D1 (de) Verfahren zur kontrolle von schadorganismen in kulturen von bt-baumwolle
HUP0003825A3 (en) Method for preparing solution with high chloramine contentration and its use
ZA988921B (en) 3,4-diarylthiazolin-2-one or -2-thione derivatives their methods of preparation and their uses in therapeutics
NO992693D0 (no) Celledelt radiosystem med forbedrede egenskaper i grenseomrÕder
FI970097L (fi) Proteiinit, jotka ovat peräisin nisäkkäiden maksasta ja niiden käyttö onkologiassa
DE69906173D1 (de) Verfahren zur Herstellung von Oxyalkylenderivaten in Gegenwart von Phosphinoxiden
IL109717A0 (en) Cell surface proteins and methods for the preparation and use thereof
AU4910299A (en) Gene and protein involved in liver regeneration
DE59805666D1 (de) Aliphatische Alkanale mit verbesserter Lagerstabilität und Verfahren zur Verbesserung der Lagerstabilität
NO20002436D0 (no) Sammensetning og fremgangsmÕte for fjerning av fosfationinnholdet i vann

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20170620